Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8808010 | 0.93 | MEN1 (0.35) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL8807303 | 0.72 | — | — | |
| SCHEMBL3810678 | 0.68 | MAPT (0.39) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL3817613 | 0.64 | GAA (0.43) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL9505628 | 0.56 | SMN1; SMN2 (0.53) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL11376019 | 0.54 | MEN1 (0.33) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL8807708 | 0.52 | — | — | |
| SCHEMBL11697181 | 0.52 | — | — | |
| SCHEMBL20144683 | 0.51 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL31419166 | 0.51 | MEN1 (0.37) | MAPTMEN1KMT2AALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851215-B1 | WATER-SOLUBLE TETRAZOLIUM SALTS | BAYER HEALTHCARE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| CN-102643274-A | Water-soluble tetrazolium salts | BAYER HEALTHCARE LLC | 2012-08-22 | — | — | CN | disclosed |
| US-7897331-B2 | Process of using a tetrazolium salt | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100255506-A1 | PROCESS OF USING A TETRAZOLIUM SALT | BAYER HEALTHCARE LLC (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767822-B2 | Water-soluble tetrazolium salts | BAYER HEALTHCARE LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080125471-A1 | Water-Soluble Tetrazolium Salts | ASCENSIA DIABETES CARE HOLDINGS AG (CH) | 2008-05-29 | — | — | US | disclosed |
| CN-101115750-A | Water soluble tetrazolium salts | BAYER HEALTHCARE LLC (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1851215-A1 | WATER-SOLUBLE TETRAZOLIUM SALTS | Bayer Healthcare, LLC (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006076619-A1 | WATER-SOLUBLE TETRAZOLIUM SALTS | BAYER HEALTHCARE LLC (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-0476456-B1 | Substituted 2-thiazolyl tetrazolium salt indicators | BAYER AG (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0476454-B1 | Analytical method using tetrazolium salt indicators having a reflectance plateau | BAYER AG (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5322680-A | Chromogenic detector for medical diagnosis by forming formazan dyes chemical reduction | MILES INC. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0432563-B1 | 4-Substituted-5-chloro-2-hydrazino thiazols | BAYER AG (DE) | 1994-03-09 | — | — | EP | disclosed |
| US-5126275-A | Chromogenic reducing indicators for reducing substances such as NADH | MILES INC. (US) | 1992-06-30 | — | — | US | disclosed |
| EP-0476454-A1 | Analytical method using tetrazolium salt indicators having a reflectance plateau | Bayer Corporation (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0476456-A2 | Substituted 2-thiazolyl tetrazolium salt indicators | Bayer Corporation (US) | 1992-03-25 | — | — | EP | disclosed |
| US-5068343-A | Fungicides for plants | BAYER AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0432563-A2 | 4-Substituted-5-chloro-2-hydrazino thiazols | BAYER AG (DE) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125471-A1 | Water-Soluble Tetrazolium Salts | TST, AASDHPPT, APRT | MAPT 330/4885MEN1 4265/4885KMT2A 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.